The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant

详细信息    查看全文

• 作者：Maria Rendina ; Antonio Schena ; Nicola Maurizio Castellaneta ; Francesco Losito ; Anna Cinzia Amoruso ; Giovanni Stallone ; Francesco Paolo Schena ; Alfredo Di Leo ; Antonio Francavilla
• 关键词：HCV ; Hepatitis ; Haemodialysis ; Peginterferon ; Ribavirin ; Kidney ; Transplant
• 刊名：Journal of Hepatology
• 出版年：2007
• 出版时间：May 2007
• 年：2007
• 卷：46
• 期：5
• 页码：768-774
• 全文大小：134 K

文摘

Background/Aims

We undertook a pilot study to investigate the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed chronic HCV patients awaiting renal transplant.

Methods

Patients received peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day for 24 or 48 weeks (genotype non-1 and 1, respectively). The dose of ribavirin was tailored according to plasma concentrations and to haemoglobin levels. Outcomes in treated patients were compared with those of a matched untreated control group.

Results

Thirty-five patients received treatment, while 35 served as untreated controls. Thirty patients completed treatment; patients were withdrawn due to transplantation (n = 2), severe anaemia (n = 1), dermatitis (n = 1) and non-response (n = 1) resulting in a drop-out rate of 14 % . Overall, 34/35 treated patients were HCV RNA negative at week 4 and had undetectable RNA at the end of treatment, compared with none of the untreated controls (ETR 97 % vs 0 % ; p < 0.001). Moreover, all achieved sustained virological response after 24 weeks of treatment-free follow-up versus no control patients (SVR 97 % vs 0 % ; p < 0.001).

Conclusions

In this study, we have shown for the first time in a large cohort of patients that HCV-patients on haemodialysis can be treated successfully with peginterferon alfa-2a (40 kDa) plus ribavirin.